30th May 2022 | Pharma Updates
DFE Pharma establishes new Center of Excellence in Hyderabad
DFE Pharma DFE Pharma, a global leader in pharma- and nutraceutical excipient solutions, has announced the opening of its new Center of Excellence ‘Closer to the Formulator’ (C2F) in Hyderabad.
JB Chemicals and Pharma revealed its new brand identity
JB Chemicals & Pharmaceuticals has rebranded as JB while maintaining its core value of ‘Good people for good health. ‘ During a recent conference in Mumbai, the company announced its new identity.
Sun Pharma acquires Uractiv portfolio from Fiterman Pharma
Sun Pharma announced that its subsidiary, S.C. Terapia, has acquired the Uractiv portfolio from Fiterman Pharma in Romania for an undisclosed sum.
Aurobindo Pharma subsidiary receives USFDA approval for cancer treatment
The pharmaceutical company announced on Thursday that its wholly owned subsidiary, Eugia Pharma Specialties, had received final FDA approval to manufacture and market pemetrexed for injection.
Strides Pharma received FDA approval for Ibuprofen oral suspension
Strides Pharma Science (Strides) announced that its step-down wholly owned subsidiary, Strides Pharma Global, Singapore, has received FDA approval for Ibuprofen oral suspension USP, 100 mg/5 mL.
FDA approved BMS' Opdivo for late-stage oesophageal cancer
FDA has approved two combination drug regimens based on Bristol-Myers Squibb’s PD-1 inhibitor Opdivo for previously untreated advanced esophageal cancer, encroaching on territory held by Merck & Co’s rival Keytruda.
J&J's proposal to import and manufacture paliperidone rejected by CDSCO Panel
Subject Expert Committee (SEC) of CDSCO has rejected Johnson and Johnson’s proposal to import and manufacture the antipsychotic drug Paliperidone Palmitate Prolonged Release Suspension, citing a lack of unmet need.